# Humacyte

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/humacyte

- Industry: Biotechnology
- Headquarters: Durham, US
- Website: www.humacyte.com
- Total disclosed funding: $225M
- Latest round: Series C (Feb 23, 2018)
- Investors on record: 5

## About

Based in North Carolina, and founded in 2004 US, Humacyte, Inc. is a biotechnology company that develops human tissue-based products for vascular diseases and replacement of anatomical conduits. The company was co-founded by Dr. Laura Niklason, Dr. Niklason, Dr. Shannon Dahl, and Dr. Juliana Blum and has approximately 122 employees. The company has raised a total of USD 664 million in 9 venture funding rounds.

The company's platform utilizes technology to engineer human, extracellular matrix-based tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues that enable patients to significantly improve treatment outcomes, including those with vascular disease and those requiring hemodialysis.

The company generates revenue through developing pharmaceutical therapies.

The company plans to expand its market and has 2 Phase 3 ongoing trials that are expected to have results by 2023.

## Funding rounds

- Series C, Feb 23, 2018, $75M — Pointstate Capital
- Series B, Oct 20, 2015, $150M — Bangkok Bank, Access Industries, Pacific Eagle Asset Management, Reignwood Group

## Investors

- Bangkok Bank — Series B
- Access Industries (https://capitalatlas.ai/funds/access-industries) — Series B
- Pacific Eagle Asset Management — Series B
- Reignwood Group — Series B
- Pointstate Capital (https://capitalatlas.ai/funds/pointstate-capital) — Series C